- NEWS
CureVac COVID vaccine let-down spotlights mRNA design challenges
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 594, 483 (2021)
doi: https://doi.org/10.1038/d41586-021-01661-0
References
Sheikh, A., McMenamin, J., Taylor, R. & Robertson, C. Lancet https://doi.org/10.1016/S0140-6736(21)01358-1 (2021).
Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. N. Engl. J. Med. https://doi.org/10.1056/NEJMc2104974 (2021).
Kremsner, P. et al. Preprint at MedRxiv https://doi.org/10.1101/2020.11.09.20228551 (2020).
Karikó, K., Buckstein, M., Ni, H. & Weissman, D. Immunity 23, 165–175 (2005).
Six months of COVID vaccines: what 1.7 billion doses have taught scientists
Scientists zero in on long-sought marker of COVID-vaccine efficacy
Mix-and-match COVID vaccines trigger potent immune response
COVID vaccines and blood clots: five key questions
WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic
Why COVID vaccines are so difficult to compare
Rare COVID reactions might hold key to variant-proof vaccines